Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00207051 | BMS-582664 in Combination With Erbitux in Patients With Advanced Gastrointestinal Malignancies | PHASE1 | COMPLETED | 62 | — | — | Jan 1, 2006 | Dec 1, 2008 | Jan 25, 2011 | 8 | United States, Canada +1 |
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Brivanib + Cetuximab | DRUG | Tablets/IV, Oral/IV , Brivanib 800 mg + Erbitux 400 mg/m2 X 1, followed by 250mg/m2, Brivanib QD / Erbitux QW, up to 48 weeks |
Inclusion Criteria: * Diagnosis of advanced or metastatic (tumor has spread) gastrointestinal malignancy * Feeling well other than cancer diagnosis (ie lab work, no infection, etc) * Available tumor tissue sample from prior surgery * Measurable disease on scans * 4-6 weeks since prior therapy and r...